[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100526359":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":39,"centralContacts":44,"locations":51,"responsibleParty":81,"collaborators":49,"id":84,"slug":85,"hasResults":86,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":49,"eligibilityCriteria":90,"healthyVolunteers":86,"sex":91,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":49,"studyType":97,"phases":98,"briefSummary":100,"conditions":101,"keywords":49,"overallStatus":54,"whyStopped":49,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Dexmedetomidine","ACTIVE_COMPARATOR","Patients will receive injection of 1 microgram\u002Fkg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve",[13],"Drug: Dexmedetomidine",{"label":15,"type":10,"description":16,"interventionNames":17},"Ozone","Participants will receive a single local injection of 4 ml ozone (10 micrograms\u002Fml) plus to 1 ml lidocaine (1%) using a 25 G needle.",[18],"Drug: Ozone",{"label":20,"type":10,"description":21,"interventionNames":22},"Dexamethasone","Patients will receive a single local injection of 5 mL (3 mL lidocaine (1%) and 2 mL \\[8 mg\\] dexamethasone) via the same technique.",[23],"Drug: Dexamethasone",[25,31,35],{"type":26,"name":9,"description":27,"armGroupLabels":28,"otherNames":29},"DRUG","Patients will receive injection of 1 microgram\u002Fkg dexmedetomidine average (70-100-microgram) (0.7-1ml) plus 4ml lidocaine injection nearby median nerve.",[9],[30],"Precedex®",{"type":26,"name":15,"description":16,"armGroupLabels":32,"otherNames":33},[15],[34],"PubChem CID 24823",{"type":26,"name":20,"description":21,"armGroupLabels":36,"otherNames":37},[20],[38],"Decadron",[40],{"name":41,"affiliation":42,"role":43},"MAHMOUD ELGEBALY, MD","Tanta faculty of medicine","PRINCIPAL_INVESTIGATOR",[45],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},"Mahmoud T Elgebaly, MD","CONTACT","00201092415231",null,"mahmoud.talaat@med.tanta.edu",[52],{"facility":53,"status":54,"city":55,"state":56,"zip":57,"country":58,"countryCode":59,"cosmosGeoPoint":60,"geoPoint":65,"contacts":66},"Faculty of Medicine","RECRUITING","Tanta","El Gharbia","31527","Egypt","EG",{"type":61,"coordinates":62},"Point",[63,64],31.00192,30.78847,{"lat":64,"lon":63},[67,69,72,75,77,79],{"name":68,"role":47,"phone":48,"phoneExt":49,"email":50},"Mahmoud Elgebaly, MD",{"name":68,"role":47,"phone":70,"phoneExt":49,"email":71},"00201006145708","mahmoudelgebaly75@gmail.com",{"name":73,"role":74,"phone":49,"phoneExt":49,"email":49},"Ayman A yousef, MD","SUB_INVESTIGATOR",{"name":76,"role":74,"phone":49,"phoneExt":49,"email":49},"Ashraf A Abo Elsafa, MD",{"name":78,"role":74,"phone":49,"phoneExt":49,"email":49},"Ahmed E Salim, MD",{"name":80,"role":74,"phone":49,"phoneExt":49,"email":49},"Alaa M Abo Hagar, MD",{"type":43,"investigatorFullName":82,"investigatorTitle":83,"investigatorAffiliation":5,"oldNameTitle":49,"oldOrganization":49},"Mahmoud T Elgebaly,MD","Assistant Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine","100526359","dexmedetomidine-ozone-and-dexamethasone-local-injection-in-carpal-tunnel-syndrome-for-pain-relief-100526359",false,"NCT06133712","Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Pain Relief","A Comparative Study Between Dexmedetomidine, Ozone and Dexamethasone Local Injection in Carpal Tunnel Syndrome for Long- Term Pain Relief","Inclusion Criteria:\n\n* Age from 20 to 60 years.\n* Both sexes.\n* Patients with ultrasonographic evidence of mild-to-moderate carpal tunnel syndrome (CTS).\n* Inclusion criteria will include numbness and pain in the median nerve (MN) distribution persisting for minimum of 3 months , nerve conduction studies (NCS) consistent with carpal tunnel syndrome (CTS) as per the American Association of Neuromuscular and Electro diagnostic Medicine (AANEM) guidelines, and an median nerve (MN) cross-sectional area (CSA)at the wrist \\>12 mm2 suggesting mild-to-moderate CTS forms.\n\nExclusion Criteria:\n\n* Patient refusal.\n* Patients with severe symptoms and signs of CTS as identified per the American Association of Neuromuscular and Electro diagnostic Medicine (AANEM) guidelines,\\[14\\] as this is an indication for surgery,\n* Patients who show improvement on medical treatment,\n* Previous surgical or injectional CTS treatment,\n* Pregnancy ,co existence of brachial plexopathy, or thoracic outlet syndrome, polyneuropathy, radiculopathy and peripheral nerve lesion in upper limb.\n* Severe cardiovascular disease\n* Morbid obese patients (body mass index (BMI) of \\>35 kg\u002Fm2)\n* Infection at site of injection.\n* Bleeding diathesis.\n* History of thyroid deficiency, uncontrolled diabetes mellitus , rheumatoid arthritis and history of glucose-6-phosphate dehydrogenase (G6PD) deficiency\n* History of Ozone or Dexmedetomidine allergy.\n* End stage renal and hepatic disease.\n* History of inflammatory joint , connective tissue disorders, , burns, any local tissue contractures and history of wrist trauma.\n* Patients who will not consent to completing The visual analogue scale (VAS) for pain or nerve conduction study before and after injection.","ALL","20 Years","60 Years",{"count":95,"type":96},135,"ESTIMATED","INTERVENTIONAL",[99],"NA","The aim of the present study is to compare the analgesic efficacy of Dexmedetomidine, Ozone and Dexamethasone regional injection in carpal tunnel syndrome.",[102,9,15,20],"Carpal Tunnel","2025-05-22",{"date":105,"type":106},"2025-05-29","ACTUAL",{"date":108,"type":106},"2023-11-01",{"date":110,"type":96},"2025-12-01",{"name":5,"class":6},1]